Mesa Labs Declares Quarterly Dividend
April 23 2014 - 5:21PM
Mesa Laboratories, Inc. (Nasdaq:MLAB) (we, us, our, "Mesa" or the
"Company") today announced that its Board of Directors has declared
a regular quarterly dividend of $0.15 per share of common stock.
The dividend will be payable on June 16, 2014, to stockholders of
record at the close of business on May 30, 2014.
About Mesa Laboratories, Inc.
We pursue a strategy of focusing primarily on quality control
products, which are sold into niche markets that are driven by
regulatory requirements. We prefer markets that have limited
competition where we can establish a commanding presence and
achieve high gross margins. We are organized into three
divisions across seven physical locations. Our Instruments
Division designs, manufactures and markets quality control
instruments and disposable products utilized in connection with the
healthcare, pharmaceutical, food and beverage, medical device,
industrial hygiene, semiconductor and petrochemical
industries. Our Biological Indicators Division manufactures
and markets biological indicators and distributes chemical
indicators used to assess the effectiveness of sterilization
processes, including steam, gas, hydrogen peroxide and radiation,
in the hospital, dental, medical device and pharmaceutical
industries. Our Continuous Monitoring Division designs,
develops and markets systems which are used to monitor various
environmental parameters such as temperature, humidity and
differential pressure to ensure that critical storage and
processing conditions are maintained in hospitals, pharmaceutical
and medical device manufacturers, blood banks, pharmacies and a
number of other laboratory and industrial environments.
Forward Looking Statements
This press release may contain information that constitutes
"forward-looking statements." Generally, the words "believe,"
"expect," "intend," "estimate," "anticipate," "project," "will" and
similar expressions identify forward-looking statements, which
generally are not historical in nature. However, the absence of
these words or similar expressions does not mean that a statement
is not forward-looking. All statements that address operating
performance, events or developments that we expect or anticipate
will occur in the future — including statements relating to revenue
growth and statements expressing general views about future
operating results — are forward-looking statements. Management
believes that these forward-looking statements are reasonable as
and when made. However, caution should be taken not to place undue
reliance on any such forward-looking statements because such
statements speak only as of the date when made. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law. In addition,
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from our historical experience and present expectations or
projections. These risks and uncertainties include, but are not
limited to, those described in our Annual Report on Form 10-K for
the year ended March 31, 2013, and those described from time to
time in our subsequent reports filed with the Securities and
Exchange Commission.
CONTACT: John J. Sullivan, Ph.D.; President and CEO,
or John Sakys; CFO, both of Mesa Laboratories, Inc.,
+1-303-987-8000
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Apr 2023 to Apr 2024